Abstract Treatment of chronic myeloid leukemia (CML) has been drastically changed by the
emergence of the ABL tyrosine kinase inhibitor (TKI), imatinib mesylate. However, resistance …

Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook
for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence
of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary …

The advent of tyrosine kinase inhibitors (TKIs) has ushered in a new era in the management
of chronic myelogenous leukemia (CML). Imatinib, the first TKI to be approved for the …

The BCR-ABL inhibitor imatinib revolutionized the treatment of chronic myeloid leukemia
(CML). However, resistance and intolerance to imatinib have emerged as substantial clinical …

The introduction of the BCR–ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis)
revolutionized the treatment of chronic myeloid leukaemia (CML). However, most patients …

Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with
chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a …

Imatinib was the first treatment for chronic myeloid leukemia (CML) that specifically targeted
the causative BCR-ABL oncoprotein, and represented a major therapeutic advance in this …

Introduction: Approximately 33% of chronic myeloid leukemia (CML) patients discontinue
treatment with imatinib in the long-term due to resistance and/or intolerance. Second …